Equianalgesic Conversion: Morphine to Hydromorphone
10 mg of morphine equals approximately 1.5 to 2 mg of hydromorphone when administered by the same route (IV or oral). 1
Standard Equianalgesic Ratio
The National Comprehensive Cancer Network (NCCN) guidelines establish the foundational conversion ratio: 1
- 10 mg IV morphine = 1.5 mg IV hydromorphone (ratio of approximately 6.7:1)
- This same ratio applies to oral administration 1
The NCCN case example explicitly demonstrates this conversion, calculating that 10 mg IV morphine converts to 1.5 mg IV hydromorphone, which extrapolates to 2 mg/hour when accounting for the 192 mg daily morphine dose in their example. 1
Critical Dose Reduction for Opioid Rotation
When converting from morphine to hydromorphone in patients with well-controlled pain, reduce the calculated equianalgesic dose by 25-50% to account for incomplete cross-tolerance. 1
This means:
- Calculate the equianalgesic dose (10 mg morphine → 1.5 mg hydromorphone)
- Then reduce by 25-50% for safety
- Final starting dose: 0.75-1.1 mg hydromorphone for 10 mg morphine 1
If pain was poorly controlled on morphine, you may use 100% of the equianalgesic dose or even increase by 25%. 1
Evidence Quality and Variability
The conversion ratio shows significant variability across different study designs and clinical contexts:
Single-dose studies suggest hydromorphone is 8-10 times more potent than morphine (10 mg morphine = 1-1.25 mg hydromorphone): 2, 3, 4
- Anesthesiology research found 0.9-1.2 mg hydromorphone equianalgesic to 10 mg morphine 2
- Psychopharmacology studies confirmed a 10:1 potency ratio 3
Chronic dosing studies in cancer patients reveal lower ratios (3-5:1): 5, 6
- PCA studies showed a 3:1 morphine-to-hydromorphone ratio 5
- Retrospective cancer pain studies found ratios of 3.7-5:1 depending on rotation direction 6
Recent high-quality crossover trials support intermediate ratios around 5:1 for IV administration: 7, 8
- A 2023 crossover study in healthy volunteers used 0.2 mg/kg morphine vs 0.05 mg/kg hydromorphone (4:1 ratio) 7
- A 2021 systematic review concluded 5:1 is adequate for IV administration 8
Route-Specific Considerations
Intravenous/Subcutaneous: The 5-7:1 ratio (10 mg morphine = 1.5-2 mg hydromorphone) is most consistently supported. 1, 8
Oral: The same ratio applies, though bioavailability differs between drugs (morphine ~24%, hydromorphone similar). 9, 4
Epidural: A 10:1 ratio may be more appropriate, with hydromorphone causing less pruritus and urinary retention. 8
Clinical Pharmacology Differences
Hydromorphone demonstrates: 7
- Faster onset of miosis and respiratory effects (2.3 vs 3.1 hours for maximum effect)
- Greater analgesic efficacy at equianalgesic doses
- Shorter duration of respiratory depression
- Better analgesia-to-respiratory depression ratio
Both drugs show similar interindividual pharmacokinetic variability (9-31% coefficient of variation), so variability should not influence drug selection. 10
Special Population Adjustments
Renal impairment: Hydromorphone exposure increases 2-fold (moderate) to 3-fold (severe renal impairment). Start with lower doses and titrate cautiously. 9
Hepatic impairment: Hydromorphone exposure increases 4-fold in moderate hepatic impairment. Use even more conservative starting doses. 9
Avoid morphine in renal failure due to accumulation of active metabolites (morphine-6-glucuronide). 1
Common Pitfalls
- Do not use calculated MME doses directly for conversion—always reduce by 25-50% for incomplete cross-tolerance 1
- Direction of rotation matters—studies suggest hydromorphone appears more potent when rotating FROM morphine (5:1) than when rotating TO morphine (3.7:1) 6
- Single-dose equivalencies overestimate hydromorphone potency in chronic dosing scenarios 5
- Individual variability is substantial—monitor closely and titrate to effect regardless of calculated dose 1